What Is a Multidisciplinary Team (MDT) Meeting?

A multidisciplinary team (MDT) meeting is a regularly scheduled gathering where healthcare professionals from different specialties come together to review individual patient cases, pool their expertise, and agree on a coordinated plan for diagnosis and treatment. The format is most established in cancer care, where it is widely considered the gold standard for clinical decision-making, but it has spread to mental health, chronic disease management, and pediatrics. What makes these meetings distinctive is that the patient’s case is examined through multiple clinical lenses at once rather than being passed sequentially from one specialist to the next.

Who Sits Around the Table

The composition of an MDT meeting depends on the clinical area, but the principle is the same: every discipline that touches the patient’s care should have a voice. In breast cancer, for example, a typical MDT includes surgeons, medical oncologists, radiotherapists, pathologists, radiologists, and specialist nurses.¹ A lung cancer MDT would add pulmonologists. A head-and-neck team might include speech therapists and maxillofacial surgeons. Mental health MDTs bring together psychiatrists, psychologists, social workers, and occupational therapists.

The meeting typically happens at a fixed time each week. Cases are listed in advance, and someone, often a junior doctor or coordinator, prepares a summary of each patient’s history, imaging, and test results. The group reviews this information together, often projecting scans and pathology slides on screen, and reaches a consensus recommendation. That recommendation is then documented and communicated to the patient’s lead clinician, who discusses it with the patient.

How MDT Meetings Differ From Other Team Models

The word “multidisciplinary” gets tossed around loosely, but it has a specific meaning in healthcare that distinguishes it from related concepts. In a multidisciplinary approach, each professional contributes their own discipline-specific perspective. They typically assess the patient separately and then come together to share findings and coordinate a plan. An interdisciplinary approach goes further: the team members integrate their assessments into a single, unified consultation, often conducted with the patient present.² Transdisciplinary work pushes beyond both, aiming to synthesize entirely new frameworks that transcend traditional discipline boundaries.³

In practice, most MDT meetings fall squarely into the multidisciplinary category. Each specialist speaks from their own training: the radiologist reads the scan, the pathologist describes the biopsy, the surgeon considers operability, the oncologist weighs chemotherapy options. The meeting is the forum where those separate viewpoints meet. Patients are rarely in the room. The real-world MDT meeting is, in essence, a structured case conference where professionals share what they know and negotiate a treatment path together.

The Evidence on Survival

The strongest evidence for MDT meetings comes from oncology, where decades of studies have examined whether patients discussed in these meetings live longer. A systematic review and meta-analysis of cancer patients found extensive evidence of a survival benefit for those discussed at an MDT meeting, though the reported magnitude varied enormously, from a 4% to a 90% reduction in the risk of death.⁴ That wide range reflects differences in cancer type, stage, study design, and what counts as “MDT-discussed” versus not.

Individual studies help paint the picture. Among patients with advanced non-small cell lung cancer, those discussed in an MDT meeting had a median overall survival roughly five months longer than those who were not, with about a 14% reduction in the risk of death after adjusting for other factors.⁵ A study of lung cancer patients treated in a dedicated multidisciplinary center found that five-year survival rates were about a third higher than in patients receiving standard care, with an adjusted hazard ratio of 0.65.⁶

These are observational findings, and it is worth being honest about what that means. Patients routed through MDT meetings may differ from those who are not in ways that affect survival independently. Randomized trials, the gold standard for proving cause and effect, are nearly impossible here because MDT discussion is now mandated in many countries, making it unethical to randomly withhold it. The consistent direction of the evidence across cancer types and settings, though, is hard to dismiss.

How MDT Discussion Changes Treatment Decisions

One of the clearest ways MDT meetings add value is by catching diagnostic or staging errors before a patient starts the wrong treatment. In gastro-esophageal cancer, one study found that MDT review improved overall staging accuracy and resulted in only about 2% of patients being under-treated.⁷ That matters because getting the stage wrong can mean offering surgery to someone who needs chemotherapy first, or the reverse.

Once the MDT makes a recommendation, it gets followed most of the time. A study at a Japanese institution tracked implementation of MDT radiotherapy recommendations and found that about 93% were carried out. Among the 7% that were not, the most common reasons were the treating clinician’s own judgment (30%), patient preferences (27%), and disease progression between the meeting and the start of treatment (20%).⁸ Those reasons are generally reasonable: the MDT’s recommendation is not a binding order, and new information or patient wishes should take priority when warranted.

Quality Varies More Than You Might Expect

Not all MDT meetings are equally effective. An observational study that scored meetings across multiple domains found wide diversity in quality, with total scores ranging broadly across teams. The best-performing areas tended to be administrative preparation and attendance. The weakest areas were patient-centredness of decision-making and the ability to prioritize complex cases that needed more discussion time.⁹

Researchers have developed tools to measure MDT performance. The MDT-MODe (Metric for the Observation of Decision-Making) instrument, for instance, uses trained observers to assess both the quality of clinical information presented and the contributions of different team members.¹⁰ The existence of such tools reflects a growing awareness that simply holding a meeting is not enough. The quality of discussion, the range of voices heard, and the attention paid to complex versus straightforward cases all matter.

A persistent gap in many MDT meetings is the incorporation of the patient’s own priorities and preferences. In a survey of cancer program staff, the vast majority reported that their programs ask patients to discuss quality-of-life priorities, and most said they engage patients in treatment decision-making at least some of the time.¹¹ But because patients are almost never present during the MDT meeting itself, their values have to be relayed secondhand, and that transmission is imperfect. A patient’s wish to avoid a particular side effect, their living situation, or their goals for the remaining months of life can easily get lost in a rapid-fire discussion of scans and biomarkers.

Hierarchy and Who Gets Heard

Healthcare has long operated as a hierarchical system, and MDT meetings do not magically erase that. Some voices carry more weight than others, and those dynamics are rarely discussed openly.¹² A qualitative study of MDT meetings found that when team members are unfamiliar with one another, junior clinicians tend to feel nervous, defer to surgeons, and question whether their input is welcome. As team members get to know each other professionally and personally, those hierarchical barriers soften, and people feel more comfortable speaking up.¹³

Personal beliefs and ambition also shape discussions. Research on upper gastrointestinal cancer MDTs found that a clinician’s belief in a particular treatment and their previous experiences with outcomes influenced collective decision-making, sometimes as a facilitator and sometimes as a source of bias. Hierarchy was specifically identified as a barrier to open deliberation.¹⁴ If the most senior surgeon in the room has a strong preference, less experienced team members may not push back, even when the evidence would support a different approach.

MDT Meetings Outside of Cancer Care

Though oncology is where MDTs are most formalized, the model has spread widely. In community mental health, MDT meetings are used to review patients with severe mental illness. A systematic review found that success factors include defined leadership, clear team goals, good communication, and equality between team members. For patients with complex needs, teams are advised to allocate extra discussion time and maintain connections with community providers.¹⁵ That said, a separate systematic review of mental health MDT meetings found that none of the thousands of studies it screened had directly investigated what these meetings actually accomplish. Functions were only mentioned in passing, and several papers flagged a lack of clarity about the meeting’s purpose and the roles of its members.¹⁶ The evidence base in mental health, in other words, is much thinner than in cancer care.

In primary care and chronic disease management, multidisciplinary teamwork outside hospital settings has shown measurable benefits. A meta-analysis found that patients with chronic obstructive pulmonary disease had fewer hospitalization days, and patients with chronic heart failure experienced improved quality of life.¹⁷ Broader narrative findings from the same review pointed to improvements in patients’ ability to manage their own conditions and in overall satisfaction with care.

The Workload Problem

MDT meetings take significant time, and that time is unevenly distributed. A prospective study in a tertiary care hospital tracked radiology department workload and found that resident doctors spent about 75 hours per month preparing for MDT meetings, senior registrars spent about 48 hours, and consultants spent about 19 hours. The meetings themselves totaled 18 hours per month.¹⁸ The preparation burden falls disproportionately on junior staff, who review imaging, pull records, and assemble the case summaries that make the meeting run smoothly.

As the number of cancer diagnoses rises and as MDT discussion expands to more conditions, meeting lists have grown longer. Teams may discuss dozens of cases in a single session, leaving only a minute or two per straightforward case and squeezing time for the complex ones that actually need deliberation. This tension between thoroughness and throughput is one of the most common complaints among MDT participants.

Virtual and Hybrid Formats

The COVID-19 pandemic forced many MDT meetings online, and the shift uncovered both advantages and problems. A scoping review of virtual cancer MDT meetings found that reported benefits included higher attendance, the ability to discuss more cases, and improvements in team member knowledge and overall patient outcomes. Downsides included concerns about discussion quality, resource limitations, and weaker team cohesion.¹⁹

One study comparing in-person and virtual tumor boards found that virtual sessions drew significantly more attendees across all categories: attending physicians, trainees, and support staff. About 73% of survey respondents found the virtual format more time-efficient, and roughly 86% said it was easier to attend. About 90% felt confident that decision-making quality was preserved.²⁰ On the other hand, a survey of maxillofacial MDT members found that while most were satisfied with image-viewing technology, the majority perceived that engagement, teamworking, and training opportunities had deteriorated since moving to remote meetings.²¹ The informal conversations that happen before and after an in-person meeting, where a surgeon might ask a pathologist a quick follow-up question, tend to vanish in a virtual setting.

Artificial Intelligence as a Decision-Support Layer

AI tools are beginning to enter MDT workflows. A platform deployed at a Chinese hospital for lung cancer consultations generated diagnostic recommendations for hundreds of cases and provided decision-making support, reportedly increasing consultation volume and reducing the time experts spent per case.²² The idea is not to replace the team’s judgment but to pre-digest information, flag relevant guidelines, and identify patients who might be eligible for clinical trials.

A systematic review of AI-based clinical decision-support systems for surgical oncology MDTs found that their agreement with human MDT recommendations ranged from about 23% to 99%, depending on the type of system and the clinical context. Decision-tree and knowledge-based systems generally showed higher concordance with guideline-based care, while IBM’s Watson for Oncology performed inconsistently across regions. Implementation challenges included technical limitations, variations in healthcare systems, and patient-specific factors that algorithms struggle to capture.²³ The technology is promising for routine cases and triage, but the complex cases that most need MDT discussion are precisely the ones AI handles least reliably.

What MDT Meetings Cost

Running MDT meetings is expensive. You are assembling a room of senior clinicians whose time is among the most costly in any hospital. A scoping review of the economics of oncology MDTs concluded that while MDTs are widely used, their cost-effectiveness has not been established. The evidence suggests they are an expensive service whose effectiveness varies with the mix of attendees, the patient population, the meeting format, and the specific hospital setting.²⁴

A systematic review of MDTs in secondary care found mixed results and noted that none of the included studies reported how potential savings from better decision-making might offset the costs of preparing for, administering, and attending the meetings.²⁵ In primary care settings, the picture is somewhat brighter: a scoping review found that a majority of cost-focused studies showed positive impacts, with cost decreases ranging from 13% to 38% over periods of six to twelve months.²⁶ The difference may reflect the fact that primary-care MDTs often reduce expensive downstream events like hospitalizations and emergency visits, while hospital-based cancer MDTs add a layer of cost on top of already expensive treatment.

Legal Gray Areas

When an MDT makes a recommendation and something goes wrong, who is responsible? This question remains surprisingly unresolved. A review of medicolegal considerations in multidisciplinary cancer care identified several persistent issues: patient consent and privacy during meetings (since case details are shared with a large group), professional liability for the collective recommendation, how dissenting views should be formally expressed, and the overall duty of care.²⁷

Currently, all members present at an MDT meeting are considered responsible for the group’s recommendation, but it is unclear whether the primary burden falls on the patient’s lead clinician. If the team cannot reach consensus, it is also unclear how a dissenting member would be viewed legally. Because there is little case law specifically addressing MDT decision-making, the situation remains ambiguous.²⁸ For now, the practical advice is that clinicians should document their reasoning carefully, record any dissenting opinions, and ensure that the patient is informed about the MDT’s recommendation before treatment proceeds.

The Training Function Nobody Talks About

MDT meetings serve a secondary purpose that rarely appears in their formal justification: they are one of the most immersive learning environments available to medical trainees. A study of residents’ experiences found that learning to participate in MDT meetings is helped when supervisors explicitly recognize the educational function of the meetings, give residents responsibilities such as presenting cases, and create conditions where juniors feel safe contributing to discussion. Interviewees consistently called for more structured training, including simulation exercises, to build the communication and behavioral skills needed to participate effectively.²⁹

A pilot survey of surgical trainees found consistently positive views about the educational value of MDT meetings, including for “non-technical skills” like communication, teamwork, and decision-making under uncertainty. Trainees recommended that active participation, through case preparation, presentation, and discussion, be built into training requirements rather than left to chance.³⁰ For a junior doctor learning oncology, watching a pathologist, a radiologist, and a surgeon negotiate the meaning of an ambiguous scan in real time teaches something that no textbook can replicate. The challenge is that rising case volumes put pressure on teams to speed through discussions, which can marginalize the educational component in favor of getting through the list.